Table 2.
Concentration of PGRs (mg/L) | Viability (%) | Browning (%) | Callus induction (%) | Callus weight (mg/explant) |
---|---|---|---|---|
3 NAA + 1 Kin | 91.33 ± 4.00ab | 8.67 ± 4.00cd | 18.17 ± 3.60a | 455.737 ± 17.445b−e |
3 NAA + 1 BAP | 83.70 ± 5.98bc | 16.30 ± 0.50abc | 19.00 ± 3.79a | 814.529 ± 252.15b−e |
3 2,4-D + 1 Kin | 88.30 ± 5.03ab | 11.89 ± 3.18bcd | 15.32 ± 3.89ab | 66.444 ± 39.585de |
3 2,4-D + 1 BAP | 90.82 ± 3.50ab | 9.17 ± 3.53cd | 16.00 ± 3.83ab | 103.150 ± 41.373de |
3 NAA + 3 Kin | 78.80 ± 6.07c | 21.19 ± 4.07a | 14.49 ± 3.92abc | 987.000 ± 28.824bc |
3 NAA + 3 BAP | 77.66 ± 6.18c | 22.33 ± 4.18a | 18.35 ± 3.13a | 851.095 ± 30.287bcd |
3 2,4-D + 3 Kin | 76.80 ± 5.23c | 23.19 ± 3.43a | 10.14 ± 3.46abc | 78.800 ± 48.109de |
3 2,4-D + 3 BAP | 83.21 ± 5.62bc | 18.06 ± 3.01ab | 20.15 ± 3.14a | 488.714 ± 19.267b−e |
5 NAA + 1 Kin | 91.97 ± 4.18ab | 9.03 ± 4.18cd | 11.85 ± 3.69abc | 154.706 ± 83.611de |
5 NAA + 1 BAP | 89.30 ± 4.07ab | 10.70 ± 4.07bcd | 3.67 ± 3.67bc | 53.647 ± 53.647de |
5 2,4-D + 1 Kin | 91.66 ± 3.76ab | 8.33 ± 3.76cd | 0.98 ± 0.98c | 2.765 ± 2.765e |
5 2,4-D + 1 BAP | 91.24 ± 4.04ab | 9.93 ± 4.48bcd | 10.29 ± 3.31abc | 112.353 ± 53.227de |
5 NAA + 5 Kin | 96.98 ± 1.65a | 3.32 ± 1.58d | 15.47 ± 3.68ab | 222.167 ± 92.369cde |
5 NAA + 5 BAP | 96.14 ± 1.84a | 5.25 ± 1.91d | 14.09 ± 3.41abc | 1073.722 ± 63.623b |
5 2,4-D + 5 Kin | 91.20 ± 5.05ab | 8.79 ± 3.05cd | 15.98 ± 3.46ab | 1804.833 ± 85.304a |
5 2,4-D + 5 BAP | 92.90 ± 3.14a | 7.09 ± 3.14d | 11.73 ± 2.90abc | 342.063 ± 179.899b−e |
In each column, different letters indicate a significant difference (P ≤ 5%) according to Duncan’s Multiple-Range Tests (DMRTs)